Pipeline

Glycan-Mediated Protein Degradation

High Unmet Medical Need

  • Addressing unmet medical need in inflammatory, autoimmune and cancer disease
  • Targeting diseases that are difficult to treat

Innovative Approach

  • Exploiting natural protein degradation pathways
  • Harnessing specific glycan structure dependent endocytosis/lysosomal degradation pathways of different cells and tissues
  • Significant potential for novel therapeutics development

Glycan-Targeted Immunotherapy

High Unmet Medical Need

  • Urgent need for new therapeutic approaches in several cancer indications
  • Side effects of current treatments are significant; need for truly cancer-specific therapeutic targets

Innovative Approach

  • Aberrant glycan antigens in cancer known to be prime targets for immuno-oncology: highly tumor specific 
  • Low immunogenicity of oncoglycans has hindered mAb development to date
  • Breaking the immune tolerance through glycoengineered oncoglycan antigen exposed on a highly immunogenic lipid particle > highly specific mAb generation
  • Production of glyco-optimized mAbs with superior efficacy
  • Supported by CHF 0.8M Switzerland Innosuisse grant

Sialic Acid-Mediated Therapy

High Unmet Medical Need

  • Despite TNFα inhibitors being the preferred and best first-line treatment, they suffer from significant primary and secondary treatment failure: more than 40% of patients lose response after 1 year
  • Treatment with TNFα inhibitors is complemented with corticosteroids and immunosuppressants to manage inflammation and ADA induction

Innovative Approach

  • CGP-201 combines novel glycan-mediated functions with the well-known and validated TNFα neutralization effect
  • Full enabling of Fc effector functions, enhanced ADCC and recruitment of wound healing macrophages, and reduction in anti-drug antibodies (ADA) can significantly enhance efficacy and result in a continuous and higher response
  • Higher efficacy in terms of clinical remission of CGP-201 is expected due to higher potency and lower ADA